A Role for Leucine-Rich α2-Glycoprotein in Leukocyte Trafficking and Mucosal Inflammation in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Takashi Mishima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immune Signal, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan. Hauptthemen laut MEDLINE: Intestinal Mucosa, Inflammatory Bowel Diseases, Colitis, Glycoproteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: AMED.
Abstract (Originalsprache)
Background
Leucine-rich α2-glycoprotein (LRG) has been identified as a disease activity marker that reflects pathology of inflammatory diseases including inflammatory bowel disease (IBD). Whereas LRG was reported to modulate transforming growth factor beta-1 (TGF-β) signaling, the role of LRG in inflammatory diseases has not been fully clarified. Here we investigated the role of LRG in IBD.
Methods
First, we investigated the difference of pathologies between wild-type (WT) mice and LRG-deficient (LRG−/−) mice in dextran sodium sulfate (DSS)-induced experimental colitis. Next, we analyzed the role of LRG in colonic inflammation by using in vitro assay.
Results
Prompt LRG upregulation was detected on the colonic epithelial cells on day 1 post 3% DSS treatment. Body weight loss after DSS treatment was significantly less severe in LRG−/− mice than in WT mice. Histological examination disclosed that leukocyte infiltration in colonic tissue was attenuated in LRG−/− mice compared with WT mice on day 3. Interestingly, the expression of endoglin, one of adhesion molecules in vascular endothelial cells, was markedly elevated in WT mice on day 1 post-DSS treatment, but was not in LRG−/− mice. Anti-TGF-β antibody treatment in mice with DSS colitis revealed that TGF-β is critical for endoglin upregulation in endothelial cells. Importantly, recombinant LRG when added to the culture media enhanced TGF-β1-induced endoglin expression in endothelial cells and increased adherence of monocytes to endothelial cells.
Conclusions
Our data suggest that LRG accelerates the progression of colonic inflammation at least in part by enhancing leukocyte trafficking through the upregulation of TGF-β1-induced endoglin expression in vascular endothelial cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immune Signal, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan.
- Department of Biological Safety Research, Japan Food Research Laboratories, Chitose, Japan.
- Division of Allergy and Rheumatology, Department of Internal Medicine, School of Medicine Iwate Medical University, Yahaba, Japan.
- Department of Anatomy and Regenerative Biology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Japan.
ORCID-Profile: Takashi Mishima, Minoru Fujimoto, Yuji Suzuki
Förderung
- AMED
Zitieren
APA
Mishima, T., Fujimoto, M., Urushima, H., Funajima, E., Suzuki, Y., Ohkawara, T., Murata, O., Serada, S., & Naka, T. (2025). A Role for Leucine-Rich α2-Glycoprotein in Leukocyte Trafficking and Mucosal Inflammation in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf022
Vancouver
Mishima T, Fujimoto M, Urushima H, Funajima E, Suzuki Y, Ohkawara T, et al. A Role for Leucine-Rich α2-Glycoprotein in Leukocyte Trafficking and Mucosal Inflammation in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf022
BibTeX
@article{Mishima2025,
author = {Mishima, Takashi and Fujimoto, Minoru and Urushima, Hayato and Funajima, Eiji and Suzuki, Yuji and Ohkawara, Tomoharu and Murata, Okinori and Serada, Satoshi and Naka, Tetsuji},
title = {A Role for Leucine-Rich α2-Glycoprotein in Leukocyte Trafficking and Mucosal Inflammation in Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf022}
}
EUVIMED